Unternehmensprofil · Healthcare

Royalty Pharma Plc

RPRX · USA
Branche
生物制药特许权
Börse
USA
Land / Region
USA
Börsengang
25. März 1993
Mitarbeiter
100
Website
www.royaltypharma.com
Aktueller Kurs
$56.66
Live · 5. Oktober 2026
Fairer Kauf
≤ $40
Einstieg mit Sicherheitsmarge
Baillie-Wachstumsscore
50/100
Mittel
Buffett Score
58/100
Mittel
Innerer Wert · Drei-Stufen-Bereich Aktueller Kurs $56.66 Live · Innerhalb des fairen Bereichs des inneren Werts

Zusammengesetzter Bewertungsbereich · konservativ $36–$40 / fair $52–$66 / optimistisch $84–$90. Bei $56.66, Innerhalb des fairen Bereichs des inneren Werts.

Bei Veröffentlichung $58.41 (20. September 2026)

Finanzüberblick
Marktkapitalisierung33,03 Mrd. $
Umsatz (TTM)2,54 Mrd. $
EBITDA1,56 Mrd. $
Nettomarge32,02 %
ROE13,97 %
KGV (TTM)30,9
Erwartetes KGV29,41
PEG1,34
EPS1,85 $
Dividendenrendite1,58 %
52-Wochen-Spanne34,56 $ – 64,38 $
Analysten-Kursziel65,13 $
Analystenbewertung4.5 / 5

Daten von EODHD, dargestellt in der Berichtswährung; nur zu Informationszwecken, keine Anlageberatung.

Über das Unternehmen

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Hintergrund

Geschichte

DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.

Branchenposition

DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.

Analysen zu dieser Aktie
50/100 Halten Royalty Pharma: $3.254bn of Portfolio Receipts and 48% Deal Share Meet a 24% Expiry Wall by 2030 and a $58.41 Price That Already Pays for the Platform Royalty Pharma is a specialty-finance platform whose loan book is denominated in molecules: it buys contractual percentages of other companies' drug sales, funds late-stage development in exchange for synthetic royalties, and collects near the top of the income statement while somebody else carries the commercial cost. 2025 Portfolio Receipts were $3.254bn against only $288m of cash operating and professional costs, and the company sourced 48% of announced biopharma-royalty transaction value over 2020-2025, but roughly 24% of 2025 Royalty Receipts sits on products whose royalty duration substantially ends by 2030, and hitting the $4.7bn 2030 target needs $2.0-2.5bn of deployment every year. Rating Hold: at $58.41 the shares are near 11.6 times estimated 2026 Portfolio Cash Flow but 19-23 times owner earnings once $1.1-1.4bn of replacement deployment is charged as economic maintenance, above the $46-50 conservative value, so the report waits for $36-40 before committing new capital. Royalty Pharma plcRPRX · USA生物制药特许权20. September 2026